Trial Profile
Clinical Trials Insight: 700030233
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2008
Price :
$35
*
At a glance
- Drugs Rufinamide (Primary)
- Indications Epilepsy; Generalised anxiety disorder; Lennox-Gastaut syndrome
- Focus Pharmacodynamics
- Sponsors Synosia Therapeutics
- 31 Jan 2008 New trial record.